Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas
Glioma is a type of tumor occurring in the central nervous system. In recent decades, specific gene mutations and molecular aberrations have been used to conduct the glioma classification and clinical decisions. Siglec10 is a member of the sialic acid-binding immunoglobulin superfamily. In this stud...
Main Authors: | Hesong Wang, Yanyan Feng, Yuxiang Zhang, Ting Wang, Heng Xu, Yuxing Zhi, Yuyin Feng, Lichun Tian, Kai Yuan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.873655/full |
Similar Items
-
The Paired Siglecs in Brain Tumours Therapy: The Immunomodulatory Effect of Dexamethasone and Temozolomide in Human Glioma In Vitro Model
by: Przemyslaw Wielgat, et al.
Published: (2021-02-01) -
Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas
by: Jinchao Wang, et al.
Published: (2023-05-01) -
Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma
by: Quan Chen, et al.
Published: (2023-05-01) -
Siglecs as Therapeutic Targets in Cancer
by: Jackwee Lim, et al.
Published: (2021-11-01) -
Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy
by: Yingyan Yu, et al.
Published: (2023-05-01)